MGMT and central nervous system cancer: Studies focusing on differentiating glioblastoma from brain metastasis, glioma grading, MGMT methylation status prediction, and tumor recurrence localization have consistently employed models such as RF, CNN, and SVM, achieving sensitivity values ranging from 66 to 91.67%, specificity from 66 to 98.75%, accuracy from 67 to 98.1%, and AUC values between 0.646 and 0.992 [2, 7, 9, 16, 17, 56, 61, 62].